Patents by Inventor Linda L. Brockunier
Linda L. Brockunier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10123995Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: GrantFiled: January 15, 2016Date of Patent: November 13, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Eric Mertz, Weiguo Liu, Scott D. Edmondson, Amjad Ali, Ying-Duo Gao, Santhosh F. Neelamkavil, Sung-Sau So, Remond Moningka, Wanying Sun, Alan Hruza, Linda L. Brockunier
-
Publication number: 20180000795Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: ApplicationFiled: January 15, 2016Publication date: January 4, 2018Applicant: MERCK SHARP & DOHME CORP.Inventors: Eric Mertz, Weiguo Liu, Scott D. Edmondson, Amjad Ali, Ying-Duo Gao, Santhosh F. Neelamkavil, Sung-Sau So, Remond Moningka, Wanying Sun, Alan Hruza, Linda L. Brockunier
-
Patent number: 9840512Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: GrantFiled: February 20, 2014Date of Patent: December 12, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Linda L. Brockunier, Helen Chen, Harry R. Chobanian, Matthew J. H. Clements, Alejandro Crespo, Duane E. DeMong, Yan Guo, William K. Hagmann, Karen M. Marcantonio, Michael Miller, Barbara Pio, Christopher W. Plummer, Dong Xiao
-
Patent number: 9783530Abstract: The present invention provides a compound of Formula I (The chemical formula should be inserted here.) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: GrantFiled: May 22, 2015Date of Patent: October 10, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Weiguo Liu, Scott D. Edmondson, Zhuyan Guo, Eric Mertz, Anthony K. Ogawa, Sung-Sau So, Wanying Sun, Linda L. Brockunier, Amjad Ali, Rongze Kuang, Heping Wu
-
Publication number: 20170197953Abstract: The present invention provides a compound of Formula I (The chemical formula should be inserted here.) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: ApplicationFiled: May 22, 2015Publication date: July 13, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Weiguo Liu, Scott D. Edmondson, Zhuyan Guo, Eric Mertz, Anthony K. Ogawa, Sung-Sau So, Wanying Sun, Linda L. Brockunier, Amjad Ali, Rongze Kuang, Heping Wu
-
Patent number: 9493461Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.Type: GrantFiled: February 3, 2014Date of Patent: November 15, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Xing Dai, Hong Liu, Anandan Palani, Shuwen He, Zhong Lai, Ravi Nargund, Karen Marcantonio, Dong Xiao, Linda L. Brockunier, Nicolas Zorn, Qun Dang, Xuanjia Peng, Peng Li
-
Patent number: 9365574Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 24, 2011Date of Patent: June 14, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Subharekha Raghavan, John E. Stelmach, Cameron J. Smith, Hong Li, Alan Whitehead, Sherman T. Waddell, Yi-Heng Chen, Shouwu Miao, Olga A. Ornoski, Joie Garfunkle, Xibin Liao, Jiang Chang, Xiaoqing Han, Jian Guo, Jonathan A. Groeper, Linda L. Brockunier, Keith Rosauer, Emma R. Parmee
-
Patent number: 9243002Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.Type: GrantFiled: February 3, 2014Date of Patent: January 26, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Xing Dai, Hong Liu, Anandan Palani, Shuwen He, Linda L. Brockunier, Ravi Nargund, Karen Marcantonio, Nicolas Zorn, Dong Xiao, Xuanjia Peng, Peng Li, Tao Guo
-
Publication number: 20160002255Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: ApplicationFiled: February 20, 2014Publication date: January 7, 2016Inventors: Linda L. Brockunier, Helen Chen, Harry R. Chobanian, Matthew J. H. Clements, Alejandro Crespo, Duane E. DeMong, Yan Guo, William K. Hagmann, Karen M. Marcantonio, Michael Miller, Barbara Pio, Christopher W. Plummer, Dong Xiao
-
Publication number: 20150368246Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.Type: ApplicationFiled: February 3, 2014Publication date: December 24, 2015Applicant: MERCK SHARP & DOHME CORP.Inventors: Xing Dai, Hong Liu, Anandan Palani, Shuwen He, Zhong Lai, Ravi Nargund, Karen Marcantonio, Dong Xiao, Linda L. Brockunier, Nicolas Zorn, Qun Dang, Xuanjia Peng, Peng Li
-
Publication number: 20150361101Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.Type: ApplicationFiled: February 3, 2014Publication date: December 17, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Xing Dai, Hong Liu, Anandan Palani, Shuwen He, Linda L. Brockunier, Ravi Nargund, Karen Marcantonio, Nicolas Zorn, Dong Xiao, Xuanjia Peng, Peng Li, Tao Guo
-
Patent number: 8741910Abstract: Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.Type: GrantFiled: November 16, 2009Date of Patent: June 3, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Linda L. Brockunier, Jian Guo, Emma R. Parmee, Subharekha Raghavan, Keith Rosauer, Darby Schmidt, John E. Stelmach
-
Publication number: 20130072492Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 24, 2011Publication date: March 21, 2013Inventors: Subharekha Raghavan, John E. Stelmach, Cameron J. Smith, Hong Li, Alan Whitehead, Sherman T. Waddell, Yi-Heng Chen, Shouwu Miao, Olga A. Ornoski, Joie Garfunkle, Xibin Liao, Jiang Chang, Xiaoqing Han, Jian Guo, Jonathan A. Groeper, Linda L. Brockunier, Keith Rosauer, Emma R. Parmee
-
Publication number: 20110218202Abstract: Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.Type: ApplicationFiled: November 16, 2009Publication date: September 8, 2011Inventors: Linda L. Brockunier, Jian Guo, Emma R. Parmee, Subharekha Raghavan, Keith Rosauer, Darby Schmidt, John E. Stelmach
-
Patent number: 7307164Abstract: The present invention is directed to compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes.Type: GrantFiled: March 21, 2003Date of Patent: December 11, 2007Assignee: Merck & Co., Inc.Inventors: Linda L. Brockunier, Joseph L. Duffy, Dooseop Kim, Emma R. Parmee, Ann E. Weber